Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

CSL Limited

CSL.AX ✓ COMPLIANT ☆ Track — members

ASX · Healthcare · Pharmaceuticals ·

Australia Large Cap Analyst: BUY

Last Close

$119.78

▼ -1.42%

Market Cap $57.37B · Vol 806.57K

Key Metrics

P/E Ratio

N/A

FWD: 18.80

Market Cap

$57.37B

Large Cap

Div Yield

2.41%

Semi-annual dividend

EPS Growth

-2.53%

YoY

RSI (14)

45.99

Momentum

Beta

0.53

vs Market

52W High

$159.47

17.09% below

52W Low

$64.51

86.71% above

Volume

806.57K

Avg 1.38M

P/B

2.57

Price-to-book

ROE

18.15%

Return on equity

Free Float

99.98%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, CSL Limited (CSL.AX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CSL.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-4.24%

+20.80%

+55.83%

+17.20%

YTD

-3.21%

-18.81%

-31.04%

-44.78%

Financials & Valuation

TTM · Annual

Total Revenue	$15.80B
Net Income	$-2,986,000,000.00
Revenue Growth (YoY)	+5.51%
Gross Margin	51.12%
Operating Margin	26.85%
Net Profit Margin	-18.90%
ROE	18.15%
ROA · ROIC	-11.19% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	18.80
PEG Ratio	N/A
P/S	2.42
P/B	2.57
P/FCF	17.14
EPS Growth	-2.53%
Outstanding Shares	479.88M

Technical Indicators

50-Day SMA	$102.59
200-Day SMA	$102.64
RSI (14)	45.99
Beta	0.53
52-Week High	$159.47
52-Week Low	$64.51

Volume Today	806.57K
Avg Daily Volume (30D)	1.38M
Relative Volume	0.59x
Volatility (10D)	15.99
Volatility (30D)	51.08
Free Float	99.98%

Analyst Consensus

BUY

Current Price $119.78

Mean Target $122.13

52W Low$64.51 52W High$159.47

Current

Target

$64.51 $159.47

Current Analyst target

+1.96% upside potential · 17 analysts

Identifiers

ExchangeASX

FIGIBBG001S7YNK1

ISINAU000000CSL8

CountryAustralia

Sub-IndustryBiopharmaceuticals

Earnings DateFeb 8, 2027

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

REGN Regeneron Pharmaceuticals, Inc. -1.48% 207940.KS SAMSUNG BIOLOGICS CO.,LTD. -0.56% UCB.BR Ucb SA +1.93% BIIB Biogen Inc. +0.80% INCY Incyte Corp -1.47%

Company Profile

CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.